Trading FDA, Clinical Trial Binary Events: $AMRN $CXSPY $AZN

. At the end of 1Q10, ChemGenex had A$14.9 million in cash and the Marketing Authorization Application (MAA) review for European marketing clearance is ongoing after being validated for review in November 2009.

3.) Get Paid to Wait: AstraZeneca (NYSE:AZN) ($45.02, $65 billion market cap, 7.6% dividend yield)

AZN is awaiting a FDA Advisory Panel review for its investigational oral anti-platelet treatment (blood thinner to reduce incidence of clots) BRILINTA (ticagrelor) on 7/28/10, seeking approval for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). A final FDA decision on the NDA is expected during late 3Q10.

On 6/2/10, the Antiviral Drugs FDA Advisory Committee voted 14-3 that motavizumab (being developed as follow-on product to SYNAGIS) should not be licensed for marketing to prevent serious respiratory syncytial virus (RSV) disease in high-risk infants with a final FDA decision expected by the end of 2Q10.

www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and pending binary events such as FDA decisions and clinical trials. The actively managed HavRx Regulatory Catalyst Index update report is currently tracking 584 entries and 381 companies (including approximately 200 stocks trading under $5 per share and 36 private companies). Promo codes (50% discount) are available for college students, investment clubs, and subscribers to my previous FDA Calendar or similar services.

Disclosure: Long AMRN, CXSPY